KRAS-IN-43 (Compound 9) is a broad-spectrum KRAS inhibitor with IC50 values of 0.15 µM for KRASG12V, 0.14 µM for KRASG12C, and 0.47 µM for wild-type KRAS. It disrupts the interaction between KRAS and cRAF and suppresses ERK phosphorylation. KRAS-IN-43 shows potential for research in KRAS mutation-associated cancers, including pancreatic, colorectal, and lung cancers.
Target:
Ras
* VAT and and shipping costs not included. Errors and price changes excepted
